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Abstract: Thyroid cancer is ranked in ninth place among all the newly diagnosed cancer cases in 2020.
Differentiated thyroid cancer behavior can vary from indolent to extremely aggressive. Currently,
predictions of cancer prognosis are mainly based on clinicopathological features, which are direct
consequences of cell and tissue microenvironment alterations. These alterations include genetic changes,
cell cycle disorders, estrogen receptor expression abnormalities, enhanced epithelial-mesenchymal
transition, extracellular matrix degradation, increased hypoxia, and consecutive neovascularization.
All these processes are represented by specific genetic and molecular markers, which can further predict
thyroid cancer development, progression, and prognosis. In conclusion, evaluation of cancer genetic
and molecular patterns, in addition to clinicopathological features, can contribute to the identification of
patients with a potentially worse prognosis. It is essential since it plays a crucial role in decision-making
regarding initial surgery, postoperative treatment, and follow-up. To date, there is a large diversity
in methodologies used in different studies, frequently leading to contradictory results. To evaluate
the true significance of predictive markers, more comparable studies should be conducted.
Keywords: thyroid cancer; molecular markers; genetic testing; thyroid cancer clinicopathological features
1. Introduction
Thyroid cancer (TC) is ranked in ninth place among all the newly diagnosed cancer
cases in 2020, with an estimated incidence of 6.6 cases per 100,000 and mortality of 0.43 cases
per 100,000 [1].
Differentiated thyroid cancer (DTC), which includes papillary cancer (PTC) and follic-
ular cancer (FTC), comprises >90% of all thyroid cancer cases [2].
The etiology of TC is not completely clear, but it is known that diverse genetic
and epigenetic changes are the driving forces of thyroid cancer development. Genetic
and molecular alterations are noticed in the vast majority (>96%) of DTCs. The thyroid
cancer progression is driven by the accumulation of genetic and epigenetic alterations
with the corresponding progressive uncontrolled activity of various signaling pathways
(e.g., MAPK and PI3K–AKT). Further, alterations of cell homeostasis, proliferation, differ-
entiation, migration, and apoptosis control are induced in response to abnormal signaling.
These processes are mediated directly or indirectly through numerous secondary molecule
derangements. Activation and further cooperation of genes and molecules, along with
the interaction between the tumor and its surrounding environment, are core aspects of
the development and progression of DTC [3–5].
The vast majority of DTC have relatively inert biological behavior and an overall
favorable prognosis. More than 90% of PTC patients have a life expectancy of over 10 years.
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However, DTC can occasionally obtain more aggressive features, as 2% of patients already
have distant metastases at the time of diagnosis [6], and up to 20% will suffer from regional
or local tumor recurrence [7]. Low-risk patients have a recurrence rate of <1%, but it could
exceed >50% in high-risk. Risk categories are determined based on clinical and pathologic
features, such as the specific histologic variant of TC, size of the primary tumor, degree of
invasion, e.g., extrathyroidal extension (ETE), vascular invasion, presence, number, and size
of locoregional lymph node metastases (LNM), etc. [8]. DTC’s outcomes can significantly
differ, from complete remission in the vast majority of cases to rapid progression and death,
suggesting large heterogeneity among cancers.
Although several scoring systems are suggested to identify low-risk and high-risk
thyroid carcinomas, they are mainly based on clinicopathological data. There is currently
no supreme criterion that would facilitate defining optimal treatment for each cancer case
individually. On the one hand, recognizing high-risk patients at the time of diagnosis would
be essential to develop new management strategies and improve follow-up; on the other
hand, it would help avoid overtreatment in low-risk patients. As representatives of cell
processes and oncogenesis, genetic and molecular markers could be highly useful for
additional risk assessment and identification of new treatment targets.
This review focuses on describing results of studies regarding the development of DTC
aggressive features, recurrence, and overall survival. To achieve this, genetic aberrations,
disarrangements of cell cycle control molecules, estrogen receptors expression patterns, in-
tensity of epithelial-mesenchymal transition molecules, matrix metalloproteinases, hypoxia,
and neovascularization molecules expressions were analyzed.
2. Genetic Aberrations Markers
Testing genetic mutations associated with TC may enhance the diagnostic value of
pre-operative cytologic examination and post-operatively the predictability of adverse
clinical outcomes.
Thyroid cancer is a genetically simple disease with a relatively low number of muta-
tions in each tumor. Some of the alterations are so-called “driver” mutations that initiate nor-
mal cell transition into cancerous. Others are called “passenger” mutations—consequences
of carcinogenesis. Alterations in BRAF, RAS, RET/PTC, and TERT promoters are assumed
as “driver” changes and could be used as diagnostic markers for cancer development [9].
2.1. BRAFV600E
The BRAF gene is altered in 66.54% of PTC patients; BRAFV600E, in particular, is
presented in 63.16% of these cases [10].
Significant heterogeneity has been noticed among literature data regarding the associ-
ation of BRAFV600E mutation and aggressive PTC features. In several large meta-analyses
and cohort studies, mutation strongly correlated with gender, LNM, absence of capsule,
ETE, tumor multifocality, advanced stage, and specific subtypes of PTC. However, there
were contradicting data regarding tumor size, patient age, and the presence of vascular
invasion [11–15]. BRAFV600E is additionally suggested as a predictive marker of PTC
recurrence or persistence, decreased efficacy of radioactive iodine (RAI) treatment [16],
and reduced overall survival [12,13,17]. At the same time, Ahn et al. and Yan et al. pre-
sented no correlation between BRAFV600E and any of the PTC features [18,19]. Li et al.
suggested that the geographical location and tumor stage should be considered when
the impact of a BRAF mutation on the cancer outcome is assessed [20].
In papillary microcarcinomas (PTMC), BRAFV600E mutation is presented in 48–51% of
cases. It is associated with larger tumor size, multifocality, ETE, LNM [21,22], and recur-
rence of PTMC [23].
BRAFV600E is suggested to have diagnostic value in the determination of cancer in fine-
needle aspiration biopsy (FNAB) material. It improves diagnostic accuracy and reduces
false-negative results. BRAFV600E positive were 23% of the indeterminate nodes [24].
Adeniran et al. reported that BRAFV600E sensitivity, specificity, positive predictive value,
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and negative predictive values for PTC in indeterminate nodules were 59.3%, 100%, 100%,
and 65.6%, respectively [25]. On average, diagnostic sensitivity increased from 81.4 to
87.4%, but false-negative results decreased from 8% to 5.2% [24]. The opposite opinion
was presented in the meta-analysis of Trimboli et al., where the BRAFV600E mutation was
found only in 5% of the indeterminate nodules; therefore, diagnostic probability and
cost-effectiveness are relatively low [26].
2.2. TERT Mutation
TelomeRASe reverse transcriptase (TERT) is the protein subunit of telomeRASe, which
adds telomeres at the end of chromosomes. At each mitosis, telomeres become shorter,
denoting cell ageing. When telomeres become critically short, cell apoptosis is induced.
TERT promoter mutation is among the most recognized markers associated with aggressive
TC phenotypes [27,28].
The average frequency of TERT promoter mutations in DTC, PTC, FTC, and dedif-
ferentiated tumors is 10.9%, 10.6%, 15.1%, and 40%, respectively. In FTC and PTC, TERT
promoter mutation is significantly associated with patients’ age, cancer size, presence of
ETE, vascular invasion, LNM, distant metastases, advanced tumor stage, persistence, or re-
currence, and disease-specific mortality [29–31]. Despite several similarities with previous
studies, Liu and Xing’s meta-analysis reported a lack of correlation with lymph node metas-
tasis. However, there was a strong trend of higher prevalence of LNM in mutation-positive
patients [32]. In addition, Liu et al. found no correlation between TERT mutation and ETE,
multifocality, and vascular invasion [33].
2.3. Combination of TERT and BRAFV600E Mutation
TERT promoter mutation frequently is found in combination with BRAFV600E muta-
tion [32,34]. A combination of BRAFV600E and TERT has been noticed in all thyroid cancer
histotypes, but it has specific significance in PTC. A significant correlation was found with
patients age, ETE, LNM, distant metastasis, disease stage, tumor recurrence, mortality,
and thyroid capsule invasion [35,36].
A combination of TERT and BRAFV600E mutations could be beneficial in the determi-
nation of cancers in intermediate nodules in FNAB. TERT promoter mutations alone have
100% specificity and only 7.0% sensitivity due to its low overall presence in thyroid can-
cers. When TERT mutations were assessed in conjunction with BRAF V600E, the diagnostic
specificity remained 100%, but sensitivity increased to 38.0%. Similarly, BRAF mutation
sensitivity increased to 32.6%, according to Liu et al. [37].
2.4. RAS Mutation
RAS mutation represents the second most commonly identified genetic mutation
in thyroid cancer.
RAS is detected in 48% of follicular adenoma (FA), 57% of FTC, and only in 21%
of PTC cases. RAS-positive DTC patients have a higher risk for RAS-mediated tumor
dedifferentiation, development of distant metastases, recurrence, and worse life expectancy.
However, association with clinicopathological manifestation is controversial [38,39]. RAS
mutation-positive patients have a 2.9 times higher risk for disease-specific death than
without RAS mutation [40].
RAS mutation status is suggested to have significant diagnostic utility for indetermi-
nate nodules in FNAB. The predictive value for cancer ranges between 74% and 88%. RAS
positivity also frequently correlates with the development of bilateral cancers. Thus, in RAS
positive indeterminate nodules, more aggressive initial therapy should be considered—
total thyroidectomy to reduce the necessity for completion reoperations that increase risks
and expenses [39,41].
On the contrary, Povoa et al. and Xing et al. found no relation between mutation
and poorer prognosis. Most patients with RAS mutation alone had a stage I diagnosis,
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usually presenting excellent responses to therapy, and were free of disease at the end of
follow-up [42,43].
2.5. RET/PTC Mutation
Clonal RET/PTC rearrangements are the most common genetic alteration found in 20–
35% of PTC cases. It is specific for this type of tumor and shows significant geographic
variations. RET/PTC could also be found in benign thyroid lesions such as thyroid
adenomas and Hashimoto thyroiditis. RET/PTC rearrangements, especially RET/PTC1
and RET/PTC3, are more frequently associated with TC following radiation exposure and
in children—with or without irradiation history. RET/PTC3 correlates with the tendency
for aggressive behavior and advanced stage. Positive cases correlate with higher rates of
ETE and LNM. The presence of a mutation in the cytological material is strongly predictive
for malignancy. The diagnostic and predictive value of RET/PTC is controversial. It is still
not considered a routine diagnostic tool in cases of indeterminate cytology [44,45].
2.6. The Cancer Genome Atlas (TCGA)—DTC Genomic Landscape
The Cancer Genome Atlas data showed that differentiated TC has one of the lowest
tumor mutational burdens, and usually harbors only a single “driver” gene alteration.
The presence of already known BRAFV600E, RAS mutations and RET fusion was described
in 59.7%, 13%, and 6.3% of PTC cases, respectively. Research also revealed previously
unknown driver genes such as EIF1AX (1.5%), PPM1D (1.2%), and CHEK2 (1.2%), thereby
decreasing genetically uncharacterized PTC cases from 25% to 3.5%.
Based on gene expression profiles, TCGA introduced a new concept of TC genetic clas-
sification. PTC was further divided into two classes that display distinctive differentiation
and signaling properties: BRAFV600E-like (BVL) and RAS-like (RL) PTC.
BVL cancers more likely have either BRAFV600E mutation or BRAF, RET, and NTRK1/3
fusions and show preeminent activation of the mitogen-activated protein kinase (MAPK)
signaling pathway. Hence, it was usually associated with the classical subtype of PTC.
RL tumors are predominantly characterized by H/N/K-RAS, EIF1AX, and BRAFK601E
point mutations and PPARG fusions and are activated by both the MAPK and PI3K/AKT
signaling pathways [46,47].
In 2016. Yoo et al. suggested a third molecular subtype—Non-BRAF-Non-RAS
(NBNR), which was mainly associated with follicular-patterned thyroid tumors. NBNR
is characterized by alteration in DICER1, EIF1AX, EZH1, IDH1, SPOP, PAX8-PPARG,
and THADA fusion [48].
Each genomic subtype activates different intracellular pathways related to cell prolif-
eration or invasiveness, including the MAPK pathway. The pattern of gradual activation
has been noticed: from NBNR to RL to BVL. Only a few NBNR tumors displayed LNM
and ETE, unlike the BVL and RL subtypes [49].
Awareness and knowledge of DTC genetic features can lead toward more accurate
diagnosis and targeted treatments.
3. Cell Cycle Control Alteration
Cell cycle proliferation and death must be regulated to maintain tissue homeostasis.
The interaction of cell cycle regulators and apoptosis activators define the destiny of
the cell. Breakdown of cell proliferation and/or apoptosis control affects the physiology
of an organism. Cell cycle dysregulation could potentially lead to different pathological
conditions, including cancer development. Understanding the linkage between the cell
cycle and apoptosis is crucial for developing new diagnostic methods and therapeutic
strategies [50].
3.1. Ki-67
The Ki-67 antigen, identified by Scholzer and Gerdes in early 1983 [51], is a protein
presented during the active phases of the cell cycle. It is absent during the inactive
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phases. Thus, if present, it is the most valuable marker to evaluate cell proliferative activity.
The percentage of tumor cells positive for Ki-67 nuclear staining is described with the Ki-
67 labeling index (LI). A high Ki-67 index at the initial diagnosis is usually associated
with a less favorable cancer phenotype and a worse prognosis. However, there is lack of
standardized cutoff value and the variability of the methodologies. Nonetheless Ki-67 has
been proven to be among most useful prognostic cancer marker in other organ systems.
Standardization of terminology reporting thyroid carcinomas regarding Ki-67 expression
risk groups is important to achieve good communication between professionals, and with
patients [52,53]. Routine Ki-67 index determination is not yet a standard practice in thyroid
cancer assessment.
Ki-67 LI has two potential applications in assessing thyroid lesions: determinations of
malignant vs. benign tumors and prediction of progression and outcome [54]. However,
in thyroid cancer cases Ki-67 role is still equivocal.
The Ki-67 is a promising marker for differentiation benign tumors from DTC, showing
high sensitivity and specificity [55–58]. If one were to look at FTC or PTC separately,
the results are somewhat ambiguous. For example, Aiad et al. suggested that Ki-67 can
differentiate PTC from FTC and even FA, but the Ki-67 index did not differ if PTC was
compared with nodular goiters [57]. Tang et al. found that nodular goiters less intensively
expressed Ki-67 than FA [56]. If comparing PTC variants: aggressive variants were more
associated with higher Ki-67 Li than classic [59]. Ki-67 expression intensity also tends to be
significantly higher in patients with concomitant thyroiditis [56].
Increased Ki-67 LI is found to be associated with several features recognized as
predictors of aggressive potential. One of them is the tumor size [55,56,59–61]. Tumors
>1 cm express Ki-67 more intensively than PTMC [56]. Linear correlation is found as
well within PTMC subgroups (<5 mm vs. ≥5 mm) [55]. These results are not exactly
consistent in all studies [54,62]. Ki-67 has been additionally associated with depth of
thyroid invasion (DTI), i.e., capsular invasion and extrathyroidal extension [49,50,54,56].
In several studies, correlation with metastatic activity was observed, but there was also wide
diversity regarding the site of metastases. Zhou et al. reported significant association with
the development of central compartment LNM [55], Miyauchi - with lateral compartment
LNM, but nothing to do with distant metastases [59]. Matsuse, Ito and Aydogan’s studies
resulted in directly opposite findings—no association with the presence of LNM [54,60,62],
only with distant spread [54,62].
Increased expression of Ki-67 was associated with worse disease-free survival (DFS)
and cause-specific survival (CSS), suggesting that cell proliferative activity in the pri-
mary tumor is a crucial factor representing the risk of persistence/recurrence and mortal-
ity [54,56,59,61–63].
Preoperative differential diagnosis between benign and malignant tumors, especially
FA and FTC, could be challenging and lead to overtreatment or inadequate choice of
surgery extent [8]. Classically, Ki-67 is evaluated in the histological specimens. Ninni Mu
et al. study reported that a high Ki-67 index in FNAB material could be an independent
predictive factor for FTC and correlated significantly with the Ki-67 index of operation
tissue specimens. It also allowed predicting extrathyroidal extension and more invasive
FTC variants [64].
3.2. p27(KIP1)
p27(KIP1) is a factor that restrains cell cycle progression by involving different molecu-
lar mechanisms. p27 functions include coordination of cell proliferation, cell differentiation,
and apoptosis [65,66]. In cancerogenesis, p27 acts as a tumor suppressor. In cancers, synthe-
sis is impaired [67]. Loss of p27 removes restraints from cyclin-CDKs and promotes tumor
progression. p27 also appears to assume a tumorigenesis stimulating role when localized
to the cytoplasm. It promotes cell motility and migration—critical events in cancer dissemi-
nation [68–70]. p27 can play both tumor suppressive and stimulating roles, therefore total
loss in cancers is rare [71].
Medicina 2021, 57, 1131 6 of 23
Several studies have assessed p27 expression in thyroid pathologies. It is suggested
as a reliable marker to distinguish FA, including atypical types, from FTC. There are also
differences in expression between minimally and widely invasive tumors. Loss of p27
is an early event in follicular carcinogenesis, which starts already in minimally invasive
carcinomas [72]. Moreover, significantly decreased p27 expression (<3.7%) is observed
in high-risk FTC patients, compared with an intermediate or low-risk group (according
to American Thyroid Association Guidelines [8]). Lower expression is also related to
more aggressive phenotype, presence of vascular invasion, and advanced tumor stage.
Although low-expressors showed a tendency for worse response to RAI therapy, shorter
DFS, and decreased median survival compared with high-expressors (84 vs. 70.3 months),
this relation did not reach the point of statistical significance [73].
In PTC, loss of p27 expression varied from 10.2% to 92.3%. It was noticed significantly
more frequently in PTC than in benign lesions. Loss of expression and cytoplasmic lo-
calization significantly correlated with aggressive behavior—the presence of LNM and
distant metastasis, in some studies also with ETE [74–79]. Regarding age, sex, tumor
size, growth characteristics of the tumor, and extrathyroidal extension, p27 showed no
significant relation [73].
Frequently cytoplasmic localization of p27 is noticed in association with a BRAFV600E
positive status [80]. Several studies have identified p27 downregulation also in non-
tumorous thyroid lesions, including Hashimoto thyroiditis and Graves’ disease [75].
3.3. Cyclin-D1
Cyclin-D1 is a nuclear protein that controls cell cycle progression of the G1/S phase.
Changes in cyclin expression result in loss of control over normal cell growth and fur-
ther induces oncogenesis. Overexpression has been noticed in various types of cancers,
including TC [79].
Cyclin-D1 is expressed more commonly in malignant than benign thyroid lesions.
With some diversities between studies, overexpression was significantly associated with
a more aggressive phenotype, including presence of extrathyroidal extension, metastatic
disease, risk of recurrence, and lack of response to treatment [81–87]. Cyclin-D1 with high
sensitivity and specificity (85% and 100%) at a certain threshold (46%) of immunolabeled
cells could also be used as a cancer predictor in FNAB material. The presence of ETE,
intraglandular metastases, and LNM were significant predictors of increased Cyclin-D1
staining [88].
3.4. Survivin
Survivin is one of the inhibitors of apoptosis protein family members that block cell
death through caspase-dependent and independent pathways. Survivin is mainly expressed
in cancers. Expression in normal tissue is negligible, therefore it has become a significant
diagnostic and prognostic marker, as well as a target for anticancer therapies [89].
Survivin expression in normal thyroid follicles is uneven and mild. It increases along
with the dedifferentiation degree [90].
The majority of PTC show moderate to high survivin immunohistochemical staining.
Higher expression is observed in tumors with LNM and distant metastases [91–94], with
a tendency for ETE and advanced stage [91,93]. Survivin expression intensity in metastatic
tissue is identical to that in initial tumors [95]. Upregulation of expression is favoring
tumor progression toward aggressive and poorly differentiated phenotype [96].
3.5. P53
The TP53 gene codes P53 protein, which stops cell cycle turnover in the G1 phase to
repair damaged DNA. The absence of a normal P53 gene and/or presence of a mutant P53
gene variant causes alterations in the repair process. In combination with inhibited apopto-
sis, it results in increased numbers of transformed cells [97]. Tumor suppressor gene P53
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mutation is the most common alteration in malignant cells, represented in approximately
half of all human cancers [98].
Several studies have reported the frequent occurrence of P53 gene mutations in undif-
ferentiated TC. However, the prevalence of alteration in well-differentiated TC, including
PTC, has not been clearly established. It ranges from 0% to 25% [97,99].
A significantly higher P53 protein expression level was noticed in malignant lesions
than in benign, thereby it could be considered as a diagnostic and prognostic marker
for PTC [81,87,98,100]. At the same time, the determination between PTC and FTC was
ambiguous [58,100]. The association between P53 and clinicopathological features of DTC
is a matter of controversy. On the one hand, Marcello et al. found a correlation with
a patients’ tumor size, multifocality, and metastatic status. On the other, Shin et al. reported
no significant correlations [98,100]. P53 was more frequently associated exclusively with
the development of dedifferentiated cancers [101] and P53’s role in the prediction of DTC
behavior is controversial.
4. Estrogen Receptors (ER)
Estrogens are a group of female hormones that play an essential role in reproduc-
tive and non-reproductive systems in females and males. In literature, the term estrogen
more frequently specifically refers to 17β-estradiol (E2) due to its significance [102]. Estro-
gen functions are mediated mainly through receptors alpha (ER-α) and beta (ER-β) [103].
Estrogens regulate cell growth, reproduction, development, and differentiation through
genomic or non-genomic pathways [102,104]. Abnormalities in E2/ER binding, signal-
ing pathways, or imbalance of ER-α and ER-β contribute to carcinogenesis and cancer
progression [103,105,106].
The global incidence of TC in women in 2020 was 10.1 per 100,000, i.e., 3-fold higher
than it is in men. The high prevalence among women, especially in fertile age and which
decreases after menopause, suggests that hormonal and reproductive factors, especially
E2, can have a significant impact on TC development and progression. [107,108]. The im-
portance of E2 in TC occurrence is also indicated by the higher rates of thyroid cancer
in women with a history of breast cancer and vice versa [109].
The presence of ER in the thyroid was first reported in 1981 by Molteni et al. Estrogen
enhances thyroid cancer cell adhesion, invasion, and migration, due to the downregu-
lation of tumor-suppressive proteins, such as catenins and cadherins. Furthermore, ER
acts on genes promoting transcription of angiogenesis factors, such as VEGF, and prote-
olytic enzymes, such as MMP-2 and MMP-9 [103,110–112]. ER-α expression in thyroid
cancers is more frequently increased, while ER-β is decreased or undetectable [103]. Dif-
ferent ER distribution and expression patterns, as well ERα/ERβ ratio, may have a role
in thyroid cancer cell proliferation, development of specific clinicopathological features,
and the outcome [105,113,114].
4.1. Estrogen Receptor-α (ER-α)
ER could be found in normal and neoplastic thyroid tissue, but the expression patterns
are different. More commonly, ER-α expression was significantly higher in clinical cancers
than in incidental tumors or non-cancerous tissue [115–118]. On the contrary, Heikkila et al.
found no difference between benign and malignant lesions. ER-α mainly was negative
in both adenomas and carcinomas [119]. Vaiman et al. did not observe immunoreactivity
for ER-α in thyroid tissue samples at all [120]. It is noticed that incidental cancers are
more frequently ER-α(-) than ER-α(+) [116,117]. No correlation was found regarding
age, gender, pre- or post-menopausal status [115,118,121,122]. These data suggest that
the intensity of ER-α expression may not be the only causative factor for the high incidence
of PTC in the female population. Another contradictory opinion was established by Rubio
et al., as ER-α expression was increased in postmenopausal papillary thyroid cancer cells
compared with non-thyroidal controls but was unchanged in premenopausal PTC. At the
same time, ER-β expression did not change in either group [123].
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Regarding tumor clinicopathological features, results vary. In some studies ER-α was
significantly associated with tumor size [115,121,124]. Different results are presented by
Huang et al. -no correlation between tumor size or TNM stage and ER-α overexpression was
noticed [122]. Magri et al. reported that T1 and T2 tumors with the increased expression of
ER-α and the loss ER-β were associated with a more aggressive tumor phenotype-presence
of capsular and vascular invasion. The correlation was lost in T3 and T4 tumors, proposing
a minor impact of ER expression on more advanced stages [116]. Rubio et al. suggested
that increased ER-α expression after menopause may be associated with papillary thyroid
cancer aggressiveness [123]. Aggressive behavior and worse overall survival also correlated
with increased ER-α/ER-β in female patients with PTC [118].
Considerably different expression patterns of ER-α make it difficult to define its true
significance in the development and progression of thyroid cancer. However, it is clear
that estrogen acting through ER-α has an impact on thyroid cell processes. It is proved
that ERα positivity was strongly associated with aggressive behavior of DTC. Furthermore,
undifferentiated, growth-prone thyroid stem and progenitor cells had 8 to 10 times higher
ER expression than differentiated thyrocytes [117,125–127].
Sturniolo et al. results, in contRASt to previous reports, suggest a significant correla-
tion of ER-α expression with remission of the disease. ER-α positive patients were more
commonly disease-free after initial treatment. ER-α expression is associated with favorable
outcome in PTC patients [124].
4.2. Estrogen Receptor-β (ER-β)
ER-β is also present in both normal thyroid tissue and cancers. The ER-β expression
does not depend on E2, thereby subsequently also on menopausal status [113,120,123,128].
Downregulation of ER-β expression, in general, is associated with tumor develop-
ment and progression [116–118]. ER-β maintains cell differentiation and the epithelial
phenotype. Thereby, decreased or absent expression of ER-β may also be a hallmark of TC
dedifferentiation [126].
ER-β(-) tumors are more commonly presented with vascular invasion than in ER-
β(+) tumors [117]. Significantly higher expression is observed in tumors without ETE,
with co-existing thyroiditis, wild-type BRAF and RAS gene mutations, and in tumors
with smaller T [118]. Moreover, reduced expression in female patients was associated with
increased prevalence of LNM and extra-thyroid spread, especially in combination with ER-α
negativity. ER-β expression was lower in those who required RAI than in the nontreatment
group [118,128]. ER-β negativity showed tendency for recurrence or persistent disease
in young female patients (<45 years old) [129].
In FTC patients, there was no correlation between low ER-β expression and gen-
der, age, tumor size, vascular or capsular invasion, metastatic status, site of metastases,
proliferative activity, TNM, or stage. Moreover, there was no correlation with tumor differ-
entiation grade, local recurrences, or serum thyroglobulin level before the first RAI therapy
episode [119].
Nevertheless, it is clear that estrogen has an important role in thyroid cancer devel-
opment, especially in females. Results frequently show a large diversity of ER expression
patterns [119]. Thereby, over- or under-expression of ER cannot be used as the only predic-
tive marker to determine cancer diagnosis, prognosis, or outcome. ER should be combined
with other markers [119,130].
5. Epithelial-Mesenchymal Transition (EMT)
An epithelial-mesenchymal transition is a complex developmental process that allows
polarized epithelial cells to suppress their epithelial features and change to mesenchymal,
assuming the qualities of mesenchymal cells: enhanced migratory capacity, invasiveness,
and higher resistance against apoptosis [131]. EMT was first discovered by Elizabeth Hay
in 1960 [132]. It is a physiological process necessary for normal embryologic development
and wound healing. In the case of pathology, signaling pathways are different from those
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in normal tissue, causing abnormal transition [133]. Pathological EMT is provided by
a complex and coordinated set of molecular changes, leading to a favorable microenviron-
ment for cancer progression and metastases formation [131,134,135]. These qualitative and
quantitative changes can be used for the evaluation of cancer development and progres-
sion [136].
The current understanding of the role of the epithelial-mesenchymal transition in TC
is that the EMT is responsible for the progression from DTC to poorly differentiated thyroid
carcinoma and anaplastic thyroid cancer [137].
5.1. E-Cadherin
E-Cadherin is predominantly detected in epithelial cells. Decreased E-Cadherin expres-
sion reduces cell-cell connections and induces EMT processes, resulting in enhanced tumor
invasiveness [137–139].
It is expressed in normal thyroid tissue and benign lesions, while its expression reduces
with the progression of differentiated TC towards undifferentiated ones. Loss of E-Cadherin
expression is noticed in the majority of anaplastic thyroid cancers [5,140–145].
There are inconclusive reports regarding E-Cadherin expression in PTC compared with
FTC, but a significant correlation was noticed regarding PTC subtypes [142–144,146]. No
significant differences were found in relation to age, gender, or ETE [142,146]. Contradictory
results were reported regarding the metastatic status and tumor stage. Several studies
found no association, other that E-Cadherin expression was significantly downregulated
in cancers with aggressive phenotype [138,142,143,147]. In both groups no correlation
with the presence of distant thyroid cancer metastasis was found. Regarding prognosis,
E-Cadherin seems to be an unreliable predictor of DFS [148].
5.2. Vimentin
Vimentin is a significant component of the intermediate filament family of proteins,
known to coordinate interactions between intermediate filaments and other cytoskeletal
elements and organelles. The increased expression has been reported in various epithelial
cancers, including gastrointestinal tumors, prostate cancer, breast cancer, CNS tumors,
TC, etc. The exact role of vimentin in cancer progression remains unclear, but increased
expression could be associated with increased tumor growth, invasion, and poor progno-
sis [5,137]. In adults, vimentin expression is limited to connective tissue mesenchymal cells,
muscle cells, and CNS [149].
Different immunostaining patterns have been identified among thyroid cancer—basal
subnuclear in most papillary carcinomas and diffuse cytoplasmic in follicular carcinomas—
but differences are insignificant. Vimentin expression levels in FTC and PTC, including PTC
subtypes, did not show relevant differences [142]. However, vimentin was more frequently
overexpressed in anaplastic cancer than in PTC [150]. Calangiu et al. found no significant
association of vimentin immunostaining and gender, age, presence of LNM, or tumor
stage [142]; Park et al. reported that expression was increased in PTC with LNM [150].
Yamamoto et al. found the opposite tendency—weaker and more focal vimentin expression
in PTC with distant metastases than those without metastases or even occult cancers [151].
Vimentin positivity was significantly associated with a reduced DFS [148]. Although
vimentin’s role in thyroid cancer development and progression is not widely described and
frequently results are contradictory, it is associated with poor prognosis in other tumors.
5.3. N-Cadherin
N-Cadherin is a cell adhesion molecule playing an important role in EMT. A common
feature of EMT is the so-called “cadherin switch”, the loss of E-Cadherin expression and
the concomitant upregulation or de novo expression of N-Cadherin. This process is associ-
ated with increased migratory and invasive ability and a worse patient prognosis [152,153].
N-Cadherin expression level was significantly higher in PTC tissue than in normal
para-carcinoma and normal non-cancerous thyroid tissue. [154,155]. N-Cadherin stimulates
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thyroid tumorigenesis through enhancing cell proliferation, colony growth and inhibiting
cell apoptosis. Additionally, N-Cadherin promotes the metastatic potential of the tumor
through extracellular matrix degradation processes, which increased MMP-2 and 14 expres-
sion, and the transcription of genes associated with induction of metastatic activity [155].
Significant differences were found between patients with and without LNM. No correlation
was found between expression and age, or gender of PTC patients, as well tumor size [154].
N-Cadherin possesses the ability to affect the cytoskeleton, cross-talk with other mem-
brane receptors, and mediate cell adhesion, suggesting that the increased activity of N-
Cadherin may facilitate the development of cancer and gain more aggressive features.
N-Cadherin has an important role in the pathogenesis and progression of multiple cancer
types, but its exact role in thyroid cancer and whether it can be used as a biomarker is still
undetermined and requires more studies [152,153].
5.4. CD44
CD44 is a universal surface molecule that exists as several isoforms and partici-
pates in multiple physiological processes. Abnormal expression and dysregulation of
CD44 contribute to tumorigenesis initiation and progression. CD44 represents a common
biomarker of cancer stem cells and promotes EMT. It is involved in cancer proliferation,
invasion, metastatic activity, and resistance against therapy. In addition, CD44 can serve
as an adverse prognostic marker among the cancer population and target for therapeu-
tic intervention [156–158]. Aberrant expression and/or dysregulation of CD44 facilitate
tumor formation in multiple organs, including lungs, ovaries, liver, glioma, and thyroid
gland [156].
CD44 variant 6 (CD44v6) is expressed only in proliferating thyroid cells, and it is
upregulated in carcinomas. In addition, upregulation is linked to aggressive behavior and
the occurrence of metastasis.
The immunohistochemical score of CD44v6 protein staining is significantly higher
in PTC specimens than in benign thyroid nodules or adjacent normal thyroid tissue [159,160].
PTC with lateral LNM showed more intensive CD44v6 staining than without metastases.
High levels of CD44v6 protein in PTC specimens may aid in the prediction of disease
progression in early-stage patients. It has the potential to be a predictive marker for
LNM. If present, individualized treatment can be initiated as early as possible [157]. In an-
other study, CD44 (not specifying isoform) alone did not show a statistically significant
association with age, gender, tumor size, LNM status, multifocality, extrathyroidal exten-
sion, or recurrence. However, there was a correlation with the combination of CD44(+)
and CD24(-). Particularly, the combination of CD44+/CD24- demonstrated a significant
association with age and gross ETE. CD44(+)/CD24(-) was also identified as an indepen-
dent prognostic factor for PTC. Combinations exhibited a statistically significant negative
association with DFS [161].
6. Extracellular Matrix Degradation
Tumor invasion is a dynamic, complex, multi-step process, which involves the detach-
ment of malignant cells from their point of origin, migration through extracellular matrix
and basement membranes, and invasion into lymphovascular channels. Breakdown or
proteolytic degradation of the basement membrane components and extracellular matrix
are essential steps for invasion. It is provided by specific proteases [162]. Matrix metallo-
proteinases (MMPs), a family of zinc-dependent endopeptidases, were first described by
Gross and Lapiere in 1962 [163]. Particularly MMP-2 and MMP-9 are important factors
of basal membrane degradation and the matter of interest in cancer research [164,165].
MMPs influence diverse physiologic and pathologic processes [166]. The function depends
on the local balance between MMPs and their physiological inhibitors. MMP expression is
upregulated in almost every type of human cancer, and their expression is often associated
with poor survival. Whereas some of the MMPs (e.g., MMP-7) are expressed by the can-
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cer cells, other MMPs (MMP-2 and MMP-9) are synthesized by the tumor stromal cells,
including myofibroblasts, fibroblasts, endothelial cells, and inflammatory cells [163].
6.1. MMP-9
MMP-9 is a member of the gelatinase group, also known as gelatinase/type IV col-
lagenase. It digests denatured collagens and gelatins and also plays a particular role
in angiogenesis by increasing the activity of proangiogenic factors [165]. Upregulation of
MMP-9 has been shown to facilitate cancer progression, invasion, and development of
metastases in various types of human malignancies [166].
MMP-9 expression is found to be greatly upregulated in thyroid carcinomas. Several
studies reported MMP-9 overexpression in samples obtained from patients with PTC,
compared with benign thyroid nodules or normal thyroid tissue [167–171]. MMPs are
involved in the stimulation of angiogenesis. It is essential for tumor growth and progres-
sion [172,173], therefore, MMP-9 expression is significantly higher among PTC patients
with larger tumor size [168,174], especially in tumors >2 cm. It is considered a depen-
dent predictor for disease status and DFS, indicating that MMP-9 correlates with the PTC
prognosis [167–169]. Higher intensity of MMP-9 expression is observed in patients with
LNM (central and/or lateral) [167,168,172,174–177]. Different results were documented
by Meng et al., who found no significant correlation between MMP-9 and lymph node
metastasis [169].
Šelemetjev et al. found a significant correlation with the degree of tumor infiltra-
tion [172]. On the contrary, Liu et al. and Zarkesh et al. groups did not find any correlation
with the presence or absence of capsule invasion, multifocality, extrathyroidal invasion,
and distant metastases [167,171]. Despite similarities with the study results by Liu et al.,
Zarkesh et al. also reported MMP-9 association with vascular invasion, as well as the ab-
sence of correlation with BRAFV600E mutation [171]. The majority of studies revealed
a positive correlation between MMP-9 expression and advanced tumor stage [164,167,172].
In contRASt, Wang et al. found no significant correlation with the advanced PTC stage [168].
When comparing expression patterns of both active and total MMP-9, active MMP-9
was presented almost only in cancer tissue and correlated with age, LNM, and ETE. On
the other hand, total MMP-9 expression had no significant correlation with any clinico-
pathological feature, suggesting that MMP-9 is activated in tumor cells. Therefore, it is
associated with aggressive tumor behavior in PTC [174]. During the follow-up, patients
with a persistent disease status had a significantly higher MMP-9 score (multiplication of
intensity and percentage of positively stained cells) than with a disease-free status. DFS
time was shorter in PTC patients with higher MMP-9 scores than with lower MMP-9
scores [167].
MMP-9 could be detected not only in thyroid tissue but also in peripheral blood
in patients with normal thyroid, benign pathologies, and thyroid cancer. Data from
peripheral blood studies correspond to thyroid tissue study data. The levels of MMP-9
in the peripheral blood of patients with DTC are significantly higher than in those with
benign thyroid disease [178–180]. No difference is found between patients with benign
thyroid disease and healthy volunteers [179,180]. It was observed that MMP-9 levels
in the peripheral blood pre- and post-operatively did not significantly change in benign
lesions, whereas in patients with DTC, post-operative MMP-9 levels were significantly
lower than pre-operative. In DTC with a higher TNM stage, tumor diameter ≥l cm,
extrathyroidal extension, or existing lymph metastasis and distant metastases, serum MMP-
9 levels were significantly higher than those reported in tumors with early TNM stage and
smaller diameter [178,180].
6.2. MMP-2
MMP-2, also known as Gelatinase A, can degrade type IV collagen. Upregulation of
MMP-2 is suggested to be associated with the malignant behavior of tumor cells, including
in PTC.
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The immunohistochemical score for MMP-2 protein staining was significantly higher
in PTC specimens than in benign thyroid nodules and adjacent normal thyroid tissue.
The results show that the increased intensity of MMP-2 staining in PTC specimens signifi-
cantly correlated with ETE and LNM and distant metastases [159,181]. The study results
by Saffar et al. suggest no relation with capsular invasion and only borderline correlation
with vascular invasion [182].
The study results of MMP-2 expression in thyroid tissue frequently correlated with
peripheral blood level evaluation. MMP-2 concentration was higher in the PTC group
than in the benign thyroid nodule group or the healthy control group. MMP-2 expression
above a certain cutoff value could help to differentiate between PTC and benign thyroid
tissue. Preoperative serum MMP-2 has a moderate predictive capacity for LNM. High
MMP-2 levels in the blood (>86.30 ng/mL) were associated with more significant risks
for the development of larger tumors (>1 cm), CLNM, LLNM, extrathyroidal invasion,
and advanced TNM stage. MMP-2 levels negatively correlated with time till recurrence.
High serum MMP-2 level was associated with a worse clinical outcome [183].
The serum concentrations of MMP-2 and MMP-9 differ significantly regarding age,
presence of microcalcification, irregular shape, diameter or number of cancer foci, and other
clinicopathological features mentioned earlier [184].
Several studies suggest that levels of MMP-2 and MMP-9 in the peripheral blood could
be used not only as predictive markers of DTC [178,179,184] but also as the efficacy criterion
for different treatment methods, e.g., surgery [168] or minimally invasive procedures, such
as UltRASound-guided Radiofrequency Ablation (RFA) [184]. Serum levels of MMP-2 and
MMP-9 could provide valuable references for diagnosing PTC before RFA and information
about procedures efficacy. In cases of DTC, MMP-2 and 9 levels were significantly lower
after RAF than before the procedure. No changes were noticed in the benign nodule
group. In combination with relevant risk factors, these serological indexes may help to
predict the prognosis of PTC before and after ablation or surgery and could have significant
implications for the PTC management planning [178,184].
7. Hypoxia End Neovascularization
Hypoxia is one of the most characteristic processes of cancer development and pro-
gression. Intensive proliferation and expansion of the tumor increase oxygen demand,
which is not always equal to supply [185], leading to self-sustaining processes such as
ischemia, neovascularization, growth, and cancer progression.
7.1. Hypoxia-Induced Transcription Factor
Hypoxia is a prominent micro-environmental component in many types of solid tu-
mors due to inadequate vascularization [186]. The cellular response to hypoxia is mediated
by the hypoxia-inducible transcription factors HIF-1 and HIF-2.
Activated Hypoxia-inducible factor 1 (HIF-1) regulates the responses of the tumor cells
to changes in oxygen concentration through transcriptional activation of genes [187–189].
HIF-1 transcriptional induction of proangiogenic factors, e.g., the vascular endothelial
growth factor (VEGF), stimulates new blood vessels development, thereby facilitating
tumor cells supply with oxygen. In addition, HIF-1 stimulates tumor metastatic activity—
the migration of cancer cells into distant and more oxygenated tissues through the tran-
scriptional activation of oncogenic factors [190,191]. HIF-1 complex, consisting of two
submits, the oxygen-sensitive HIF-1α and the constitutively expressed HIF-1β, partici-
pates in the cancer biology of numerous endocrine tumors [192]. HIF-1α and HIF-2α
have unique tissue distributions and play critical but non-overlapping roles in tumor
progression [187,193].
Cancer development and progression depend mainly on three factors—the presence
of hypoxia (HIF-1a activation), inflammation (NF-kB activation), and ER-α [103].
Several studies reported higher expression of HIF-1α and HIF-2α in TC than in nor-
mal thyroid or benign lesions [194]. The expression did not show any correlation with
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the patient’s age, gender or the presence of node calcification. However, there was a strong
correlation between HIF-2α and tumor size; it did not reach the same significance in associ-
ation with HIF-1α. HIF-1α and 2α overexpression was associated with capsular invasion
and the presence of LNM. Tumors with high HIF-1α and 2α staining had a higher TNM
stage [194]. Data suggest that HIF-1 may promote migration and aggressiveness of PTC,
FTC, and ATC [195]. HIF-1 knockdown represses cell invasion and induces apoptosis by
downregulating the expression levels of WWP9, WWP2, VEGF, and VEGFR2. Therefore,
HIF-1α could serve as a potential therapeutic target for the treatment of TC [196].
7.2. Vascular Endothelial Growth Factor (VEGF)
The vascular endothelial growth factor is the key mediator of cancer angiogenesis.
It is upregulated by oncogene expression, various growth factors, and also hypoxia [197].
Vascular endothelial growth factors are members of the platelet-derived growth factor
family of structurally related mitogens. This group of markers includes VEGF-A, placental
growth factor (PlGF), VEGF-B, VEGF-C, and VEGF-D [198].
VEGF has been identified as a significant mediator of angiogenesis in the thyroid
gland. Angiogenesis is known to play an important role in the development, growth,
and metastasizing of cancers.
VEGF-C is the most potent factor, which guides the growth of tumor-associated lym-
phatic vessels, thereby further promoting cancer spread through the lymphatic system [199].
Ceric et al. found no difference between papillary and follicular cancer [200]. However,
in another study, VEGF-C differed significantly between PTC histotypes (classic vs. follicu-
lar variant). VEGF-C did not differ between age groups and sex [95]. VEGF-C positively
correlated with tumors T status—the higher the T stage, the more intensive of an expression
of VEGF-C was observed. VEGF-C also correlated with gross ETE, and positive resection
margins [190]. A high expression was associated with the presence of lymph node metas-
tases and advanced TNM stage [95,172,200,201]. Another study compared VEGF-A and
VEGF-C, and their co-regulatory potential in different types of thyroid carcinomas. VEGF-A
overexpression was observed in undifferentiated cancers, suggesting its important role
in developing aggressive patterns. Diversities related to association between both VEGF
types and development of LNM were found. VEGF-A was highly expressed in classical
variant of PTC with LNM, but VEGF-C was significantly under-expressed. VEGF-C ex-
pression was higher in follicular variant of PTC. Results show that VEGF-A and VEGF-C
mRNA and protein productions in thyroid malignancies have a strong association and
may cross-regulate each other. It could be related to their shared receptor (VEGFR2) and
resultant feedback systems. It has been noticed that VEGF-C can stimulate angiogenesis
in addition to lymphangiogenesis [202]. The upregulation of VEGFs in human TC correlates
with cancer development, progression, and poor prognosis [187,203].
7.3. Antiangiogenic Therapy—Tyrosine Kinase Inhibitors
DTCs are highly vascular tumors, meaning that they are dependent on angiogenesis.
Angiogenesis and cancer cell growth are influenced by aberrations in cancer cell signaling.
Most of these aberrations occur as a result of mutations in tyrosine kinase and other
molecule-affected pathways (RAF/MEK/ERK and AKT/mTOR).
In recent years, angiogenesis has been intensively studied regarding the identification
of mediators that may be used as targets for new anticancer treatments.
Multiple Tyrosine kinase inhibitors (TKI) targeting RAF, MEK, and the VEGF receptors
have been identified. TKIs limit tumor growth by decreasing their blood supply. In addition,
TKI have direct anticancer activity on the tumor cells by targeting signaling molecules
within or upstream of the RAF/MEK/ERK pathway. Their efficacy on different molecular
pathways in case of recurrent/metastatic RAI refractory TC has been researched [204,205].
Several TKIs have been approved for the treatment of advanced DTC. Sorafenib is
approved for the treatment of progressive metastatic RAI refractory DTC. It inhibits VEGF1–3,
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platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), KIT, and RET receptors
and weakly RAF kinase. The response to treatment was observed in 12.2% of patients.
Another TKI, Lenvatinib, was approved in 2015 for treatment of advanced RAI re-
fractory DTC. Lenvatinib targets VEGFR 1, 2, and 3, fibroblast growth factor receptors
(FGFR) 1 through 4, PDGFR α, RET, and KIT signaling networks. It was associated with
significant improvements in progression-free survival and the response rate among patients
with RAI refractory TC. The response to Lenvatinib therapy was observed in 64.8% of
cases [204–206].
Nevertheless, TKI therapy is associated with significant improvements in progression-
free survival and the response rate among patients with treatment refractory DTC, patients
can experience adverse effects and impaired quality of life, as well substantial financial
burden [206].
8. Aggressive Variants of PTC
In addition to knowledge of the genetic and molecular impact on cancer aggressive
behavior, the role of specific morphological entities of PTC should also be recognized.
PTC usually is associated with a good prognosis and overall survival. Aggressive
behavior could be associated with the presence of rare but more aggressive PTC subtypes
such as diffuse sclerotizing variant, hobnail variant, tall cell variant, columnar variant,
or solid/trabecular variant of PTC.
Tumors harboring aggressive variants are associated with advanced stage, extrathy-
roidal extension, higher recurrence rate and decreased disease-specific survival compared
to the classical or follicular variant of PTC. The development of these tumors showed
a high correlation with gene and molecular mutations such as BRAFV600E, RAS, TERT,
RET/PTC3, and TP53. For a comprehensive assessment of DTC to predict prognosis and
formulate a more complete treatment plan, these PTC variants should be considered and
recognized [207,208].
9. Conclusions
The incidence of thyroid cancer (TC), in particular differentiated thyroid cancer (DTC),
has been increasing over the last few decades. Regarding behavior, TC can be stratified as
low, intermediate, and high risk, depending on a variety of morphological, genetic and
molecular features. The traditional “one-size-fits-all” approach to DTC should be revised
and transitioned to a more individualized and risk-adapted approach for the selection
of more appropriate initial therapy, adjuvant therapy, and follow-up of patients with
DTC. Therefore, early recognition of potentially worse cancer patterns can lead to more
timely risk assessment and prediction of adverse events, which can potentially impact DTC
patients’ destiny.
A large amount of studies has been conducted for the last few decades regarding TC
risk assessment. DTC behavior, recurrence, and survival could be predicted by analyzing
genetic and molecular markers. Nonetheless, so far, no consensus concerning the clinical
prognostic value of studied markers have been achieved.
After summarizing data from analyzed studies, we conclude that there is a large
amount of different genetic and molecular markers for the detection of the possible impact
on tumorigenesis, aggressive phenotype, recurrence, and overall survival. Therefore,
we cannot highlight one single marker which could accurately predict the possible behavior
of DTC. Frequently diverse and even contradictory results are noticed among studies.
If speculating on possible reasons, the heterogeneity of cohorts (size and characteristics)
and large diversity of methodologies should be mentioned. One more reason could
be the unequal numbers of research dedicated for the evaluation of different markers.
To determine the true significance of each marker and their role in behavior of DTC,
implication of more and comparable equally designed studies could be suggested.
There are inconsistencies due to the high diversity between study results, but some
trends could still be observed. (See in Table 1).
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BRAFV600E +/- +/- +/- +/- +/- +/- +/- +/- +/- +
TERT + + + +/- - +/- + + + +
BRAFV600E +
TERT + - n/a + + + + + + +
RAS n/a n/a n/a n/a + n/a + n/a +/- +/-
RET/PTC n/a n/a n/a + n/a + n/a n/a n/a n/a
Ki-67 +/- - +/- + - +/- +/- + +/- +
p27 - - +/- +/- - +/- + + n/a n/a
Cyclin-D1 - - +/- +/- - +/- n/a +/- +/- +
Survivin - - - + n/a + + + n/a n/a
p53 - +/- +/- +/- +/- +/- + - - n/a
ER-α - - +/- - - - - - - +
ER-β - - - + * - + */- - - - +
ER-α/ER-β + - - - - - - - n/a +
E-Cadherin - - + +/- n/a +/- - +/- - n/a
Vimentin - - n/a n/a n/a +/- - - + n/a
N-Cadherin + - + n/a n/a + n/a n/a n/a n/a
CD44 + **/- - - + **/- - + **/- n/a n/a + **/- n/a
MMP-9 +/- - +/- +/- - +/- - +/- + +
MMP-2 - - +/- + - + +/- + + n/a
HIF-1 - - - n/a n/a + n/a + n/a n/a
VEGF - - + + - +/- n/a + + n/a
“+/-”—contradictive data. “n/a”—data not available. “+”—correlation found. “-”—no correlation found. *—only in papillary cancer
(PTC). ** +CD24(-).
Most likely this field of research will be topical in future, due to the increased demand
for more accurate and individualized risk assessment and treatment.
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